Activity of CuDIPS against mammary cancer in C3H HeNCR mice.

Abstract

A copper complex with superoxide dismutase mimetic activity, Cu(II)2 (3,5-diisopropylsalicylate)4 (CuDIPS), was tested for activity against mammary cancer in female C3H/HeNCR mice. Initiation of treatment at 20 or at 30 weeks of age had a limited beneficial effect on survival rates. Further, a small, but not statistically significant, difference in tumorigenesis was observed in comparisons between experimental and control groups of animals. Implications of these findings are discussed.

• Authors: C G Crispens Jr, J R Sorenson
• Journal: Anticancer research (Anticancer Res) 1992 Jul-Aug Vol. 12 Issue 4 Pg. 1271-3 ISSN: 0250-7005 [Print] Greece
• PMID: 1503420 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Salicylates
• copper bis(3,5-diisopropylsalicylate)

Topics

• Animals
• Antineoplastic Agents (therapeutic use)
• Drug Screening Assays, Antitumor
• Female
• Incidence
• Injections, Subcutaneous
• Mammary Neoplasms, Animal (drug therapy, mortality)
• Mice
• Mice, Inbred C3H
• Salicylates (therapeutic use)
• Survival Analysis